Please login to the form below

Not currently logged in
Email:
Password:

Isoniazid

This page shows the latest Isoniazid news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

The WHO defines XDR-TB as resistance to first-line drugs isoniazid and rifampicin, as well as resistance to at least one fluoroquinolone and another second-line injectable such as amikacin,

Latest news

  • Sanofi's Priftin cleared for latent tuberculosis in the US Sanofi's Priftin cleared for latent tuberculosis in the US

    After a priority review, the FDA has approved Priftin (rifapentine) in combination with isoniazid to treat latent TB infection in patients aged two years and older. ... weeks; the combination of rifampicin and isoniazid daily for 3-4 months; and

  • Researchers develop breath test for TB Researchers develop breath test for TB

    Inhaled form of isoniazid could show almost instant results. Researchers have developed the first breath test to diagnose tuberculosis (TB). ... It uses an inhaled form of the antibiotic isoniazid that is activated by TB enzymes that are unique to the

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Treatment and management of TB infection involves long-term administration of antibiotics, primarily rifampicin and isoniazid. ... Multi drug-resistant TB (MDR-TB) is defined as resistance to the gold standard treatment of isoniazid and rifampicin.

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    In recent years, the burden of TB resistant to first-line therapy of at least isoniazid and rifampicin, the two major anti-tubercular treatments, has increased rapidly in the.

  • Janssen's Sirturo wins backing for conditional EU licence Janssen's Sirturo wins backing for conditional EU licence

    In recent years, the burden of tuberculosis resistant to first-line therapy of at least isoniazid and rifampicin, the two major anti-tuberculosis treatments, has increased rapidly in the absence of

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Could ketamine be the next big thing in depression?

    Doctors noticed that tuberculosis patients treated with isoniazid showed signs of  improved mood. ... Isoniazid is antituberclular but it also interferes with monoamine metabolism, slowing neurotransmitter breakdown once it is released.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics